Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Chang

Gastroenterology New York, NY Medical Doctor

NPI 1619995610 CMS profile 299905

1049 Park Ave, New York, NY 10028

Open in the dashboard

General payments

$71,630

1,389 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Chang of New York, NY is reported in the CMS Open Payments database as having received $71,630 across 1,389 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,358 283
2024 General $12,755 246
2023 General $3,468 214
2022 General $3,163 206
2021 General $2,661 172
2020 General $2,092 100
2019 General $17,132 168

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Chang
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Peter Chang were reported at $30,358. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Peter Chang Gastroenterology median Middle half National median
2019 $17,132 $417 $126–$1,100 $163
2020 $2,092 $224 $74–$624 $114
2021 $2,661 $352 $106–$1,054 $132
2022 $3,163 $448 $129–$1,270 $149
2023 $3,468 $533 $150–$1,390 $160
2024 $12,755 $605 $160–$1,606 $164
2025 $30,358 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $34,892 173 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $18,058 297 payments
  3. AbbVie, Inc. $5,378 284 payments
  4. Janssen Biotech, Inc. $2,679 115 payments
  5. QOL Medical, LLC $2,131 80 payments
  6. Celgene Corporation $1,290 83 payments
  7. Ferring Pharmaceuticals Inc. $885 51 payments
  8. Merck Sharp & Dohme Corporation $880 41 payments
  9. Ardelyx, Inc. $672 33 payments
  10. RedHill Biopharma Inc. $559 40 payments
  11. Other $4,205 192 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,086 10 payments
  2. Food and Beverage $26,223 1,358 payments
  3. Consulting Fee $14,000 4 payments
  4. Travel and Lodging $1,288 15 payments
  5. Long term medical supply or device loan $25 1 payment
  6. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. ENTYVIO $34,206 139 payments
  2. UCERIS $8,690 6 payments
  3. PLENVU $5,712 8 payments
  4. APRISO $2,899 2 payments
  5. XIFAXAN $2,710 210 payments
  6. RINVOQ $2,164 101 payments
  7. STELARA $1,446 66 payments
  8. ZEPOSIA $1,415 84 payments
  9. SKYRIZI $1,402 66 payments
  10. TREMFYA $1,372 50 payments
  11. Other $15,913 828 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

408

Median for Gastroenterology: 569

Drug cost

$113,175

Median for Gastroenterology: $104,976

Branded share of claims

23.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 16 $43,878
Linzess Linaclotide Brand 39 $38,562
Mesalamine Generic 24 $15,206
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 27 $4,632
Lubiprostone Generic 11 $3,205
Omeprazole Generic 131 $2,442
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 14 $1,921
Lansoprazole Generic 12 $696
Pantoprazole Sodium Generic 33 $647
Esomeprazole Magnesium Generic 17 $598

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$209,461

Of which drugs: $141,756

Medicare patients

262

Average age 75

Services billed

9,085

154 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 50%
Diabetes 29%
Ischemic heart disease 28%
Osteoporosis 27%
Cancer 22%
Depression 16%
Chronic kidney disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
$8,379 — —
SKYRIZI
$438 — —
Sucraid
$419 — —
RINVOQ
$379 — —
STELARA
$326 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

1,389 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record